PDE3 inhibition in dilated cardiomyopathy

Current Opinion in Pharmacology

Volumn 11, Issue 6, 2011, Pages 707-713

  Movsesian, Matthew ^a   Wever Pinzon, Omar ^a   Vandeput, Fabrice ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; CALCIUM ION; CYCLIC AMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; INOTROPIC AGENT; MILRINONE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; PLACEBO;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CONGESTIVE CARDIOMYOPATHY; DEFIBRILLATOR; DRUG INTERMITTENT THERAPY; ENZYME INHIBITION; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SUDDEN DEATH;

EID: 82255179436     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2011.09.001     Document Type: Review

References (60)

1. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 325 1991 293 302
2. J.N. Cohn, G. Johnson, S. Ziesche, F. Cobb, G. Francis, F. Tristani, R. Smith, W.B. Dunkman, H. Loeb, and M. Wong A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure N Engl J Med 325 1991 303 310
3. J.N. Cohn, and G. Tognoni A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N Engl J Med 345 2001 1667 1675 (Pubitemid 33126822)
4. P.A. Poole-Wilson, K. Swedberg, J.G. Cleland, A. Di Lenarda, P. Hanrath, M. Komajda, J. Lubsen, B. Lutiger, M. Metra, and W.J. Remme Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol european trial (comet): randomised controlled trial Lancet 362 2003 7 13 (Pubitemid 36835815)
5. F. Zannad, J.J. McMurray, H. Krum, D.J. van Veldhuisen, K. Swedberg, H. Shi, J. Vincent, S.J. Pocock, and B. Pitt Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2011 11 21
6. A. Sculptoreanu, E. Rotman, M. Takahashi, T. Scheuer, and W.A. Catterall Voltage-dependent potentiation of the activity of cardiac l-type calcium channel alpha 1 subunits due to phosphorylation by camp-dependent protein kinase Proc Natl Acad Sci USA 90 1993 10135 10139 (Pubitemid 23328266)
7. T. Takasago, T. Imagawa, and M. Shigekawa Phosphorylation of the cardiac ryanodine receptor by camp-dependent protein kinase J Biochem (Tokyo) 106 1989 872 877 (Pubitemid 19285912)
8. H.K. Simmerman, and L.R. Jones Phospholamban: protein structure, mechanism of action, and role in cardiac function Physiol Rev 78 1998 921 947 (Pubitemid 28491945)
9. D.J. Beuckelmann, M. Nabauer, and E. Erdmann Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure Circulation 85 1992 1046 1055
10. S. Minamisawa, M. Hoshijima, G. Chu, C.A. Ward, K. Frank, Y. Gu, M.E. Martone, Y. Wang, J. Ross Jr. , and E.G. Kranias Chronic phospholamban- sarcoplasmic reticulum calcium atpase interaction is the critical calcium cycling defect in dilated cardiomyopathy Cell 99 1999 313 322 (Pubitemid 29519910)
11. H. He, M. Meyer, J.L. Martin, P.M. McDonough, P. Ho, X. Lou, W.Y. Lew, R. Hilal-Dandan, and W.H. Dillmann Effects of mutant and antisense rna of phospholamban on sr ca(2+)-atpase activity and cardiac myocyte contractility Circulation 100 1999 974 980 (Pubitemid 29407179)
12. M. Hoshijima, Y. Ikeda, Y. Iwanaga, S. Minamisawa, M.O. Date, Y. Gu, M. Iwatate, M. Li, L. Wang, and J.M. Wilson Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac raav gene delivery Nat Med 8 2002 864 871
13. Y. Iwanaga, M. Hoshijima, Y. Gu, M. Iwatate, T. Dieterle, Y. Ikeda, M.O. Date, J. Chrast, M. Matsuzaki, and K.L. Peterson Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats J Clin Invest 113 2004 727 736 (Pubitemid 38544166)
14. K. Eizema, H. Fechner, K. Bezstarosti, S. Schneider-Rasp, A. van der Laarse, H. Wang, H.P. Schultheiss, W.C. Poller, and J.M. Lamers Adenovirus-based phospholamban antisense expression as a novel approach to improve cardiac contractile dysfunction: comparison of a constitutive viral versus an endothelin-1-responsive cardiac promoter Circulation 101 2000 2193 2199 (Pubitemid 30253049)
15. A. Watanabe, M. Arai, M. Yamazaki, N. Koitabashi, F. Wuytack, and M. Kurabayashi Phospholamban ablation by rna interference increases Ca2+ uptake into rat cardiac myocyte sarcoplasmic reticulum J Mol Cell Cardiol 37 2004 691 698 (Pubitemid 39194561)
16. L. Suckau, H. Fechner, E. Chemaly, S. Krohn, L. Hadri, J. Kockskamper, D. Westermann, E. Bisping, H. Ly, and X. Wang Long-term cardiac-targeted rna interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy Circulation 119 2009 1241 1252
17. T. Dieterle, M. Meyer, Y. Gu, D.D. Belke, E. Swanson, M. Iwatate, J. Hollander, K.L. Peterson, J. Ross Jr. , and W.H. Dillmann Gene transfer of a phospholamban-targeted antibody improves calcium handling and cardiac function in heart failure Cardiovasc Res 67 2005 678 688 (Pubitemid 41033363)
18. M. Meyer, D.D. Belke, S.U. Trost, E. Swanson, T. Dieterle, B. Scott, S.P. Cary, P. Ho, W.F. Bluhm, and P.M. McDonough A recombinant antibody increases cardiac contractility by mimicking phospholamban phosphorylation FASEB J 18 2004 1312 1314 (Pubitemid 39561587)
19. M.R. Bristow, R. Ginsburg, W. Minobe, R.S. Cubicciotti, W.S. Sageman, K. Lurie, M.E. Billingham, D.C. Harrison, and E.B. Stinson Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts N Engl J Med 307 1982 205 211 (Pubitemid 12079105)
20. M.R. Bristow, R. Ginsburg, V. Umans, M. Fowler, W. Minobe, R. Rasmussen, P. Zera, R. Menlove, P. Shah, and S. Jamieson Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure Circ Res 59 1986 297 309 (Pubitemid 17178124)
21. M. Ungerer, G. Parruti, M. Bohm, M. Puzicha, A. DeBlasi, E. Erdmann, and M.J. Lohse Expression of beta-arrestins and beta-adrenergic receptor kinases in the failing human heart Circ Res 74 1994 206 213
22. M. Ungerer, M. Bohm, J.S. Elce, E. Erdmann, and M.J. Lohse Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart Circulation 87 1993 454 463 (Pubitemid 23040915)
23. J. Neumann, W. Schmitz, H. Scholz, L. von Meyerinck, V. Doring, and P. Kalmar Increase in myocardial gi-proteins in heart failure Lancet 2 1988 936 937
24. A.M. Feldman, A.E. Cates, W.B. Veazey, R.E. Hershberger, M.R. Bristow, K.L. Baughman, W.A. Baumgartner, and C. Van Dop Increase of the 40,000-mol wt pertussis toxin substrate (g protein) in the failing human heart J Clin Invest 82 1988 189 197 (Pubitemid 18262515)
25. M.D. Feldman, L. Copelas, J.K. Gwathmey, P. Phillips, S.E. Warren, F.J. Schoen, W. Grossman, and J.P. Morgan Deficient production of cyclic amp: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure Circulation 75 1987 331 339 (Pubitemid 17007338)
26. W. Danielsen, H. v der Leyen, W. Meyer, J. Neumann, W. Schmitz, H. Scholz, J. Starbatty, B. Stein, V. Doring, and P. Kalmar Basal and isoprenaline-stimulated camp content in failing versus nonfailing human cardiac preparations J Cardiovasc Pharmacol 14 1989 171 173 (Pubitemid 19158089)
27. M. Bohm, B. Reiger, R.H. Schwinger, and E. Erdmann Camp concentrations, camp dependent protein kinase activity, and phospholamban in non-failing and failing myocardium Cardiovasc Res 28 1994 1713 1719 (Pubitemid 24344147)
28. F. Vandeput, S.L. Wolda, J. Krall, R. Hambleton, L. Uher, K.N. McCaw, P.B. Radwanski, V. Florio, and M.A. Movsesian Cyclic nucleotide phosphodiesterase pde1c1 in human cardiac myocytes J Biol Chem 282 2007 32749 32757 (Pubitemid 350159317)
29. R. Hambleton, J. Krall, E. Tikishvili, M. Honeggar, F. Ahmad, V.C. Manganiello, and M.A. Movsesian Isoforms of cyclic nucleotide phosphodiesterase pde3 and their contribution to camp hydrolytic activity in subcellular fractions of human myocardium J Biol Chem 280 2005 39168 39174 (Pubitemid 41713868)
30. W. Richter, M. Xie, C. Scheitrum, J. Krall, M.A. Movsesian, and M. Conti Conserved expression and functions of pde4 in rodent and human heart Basic Res Cardiol 106 2011 249 262
31. F. Vandeput, J. Krall, R. Ockaili, F.N. Salloum, V. Florio, J.D. Corbin, S.H. Francis, R.C. Kukreja, and M.A. Movsesian Cgmp-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium J Pharmacol Exp Ther 330 2009 884 891
32. B. Sun, H. Li, Y. Shakur, J. Hensley, S. Hockman, J. Kambayashi, V.C. Manganiello, and Y. Liu Role of phosphodiesterase type 3a and 3b in regulating platelet and cardiac function using subtype-selective knockout mice Cell Signal 19 2007 1765 1771 (Pubitemid 46935432)
33. J. Wechsler, Y.H. Choi, J. Krall, F. Ahmad, V.C. Manganiello, and M.A. Movsesian Isoforms of cyclic nucleotide phosphodiesterase pde3a in cardiac myocytes J Biol Chem 277 2002 38072 38078 (Pubitemid 35154659)
34. Y. Shakur, K. Takeda, Y. Kenan, Z.X. Yu, G. Rena, D. Brandt, M.D. Houslay, E. Degerman, V.J. Ferrans, and V.C. Manganiello Membrane localization of cyclic nucleotide phosphodiesterase 3 (pde3). Two n-terminal domains are required for the efficient targeting to, and association of, pde3 with endoplasmic reticulum J Biol Chem 275 2000 38749 38761 (Pubitemid 32009210)
35. S.J. Han, S. Vaccari, T. Nedachi, C.B. Andersen, K.S. Kovacina, R.A. Roth, and M. Conti Protein kinase b/akt phosphorylation of pde3a and its role in mammalian oocyte maturation EMBO J 25 2006 5716 5725 (Pubitemid 44967755)
36. R.W. Hunter, C. Mackintosh, and I. Hers Protein kinase c-mediated phosphorylation and activation of pde3a regulate camp levels in human platelets J Biol Chem 284 2009 12339 12348
37. B. Ding, J. Abe, H. Wei, Q. Huang, R.A. Walsh, C.A. Molina, A. Zhao, J. Sadoshima, B.C. Blaxall, B.C. Berk, and C. Yan Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure Circulation 111 2005 2469 2476 (Pubitemid 40696135)
38. M.A. Movsesian, C.J. Smith, J. Krall, M.R. Bristow, and V.C. Manganiello Sarcoplasmic reticulum-associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts J Clin Invest 88 1991 15 19
39. D.S. Baim, A.V. McDowell, J. Cherniles, E.S. Monrad, J.A. Parker, J. Edelson, E. Braunwald, and W. Grossman Evaluation of a new bipyridine inotropic agent - milrinone - in patients with severe congestive heart failure N Engl J Med 309 1983 748 756 (Pubitemid 13004282)
40. J.R. Benotti, W. Grossman, E. Braunwald, D.D. Davolos, and A.A. Alousi Hemodynamic assessment of amrinone. A new inotropic agent N Engl J Med 299 1978 1373 1377 (Pubitemid 9092478)
41. B.E. Jaski, M.A. Fifer, R.F. Wright, E. Braunwald, and W.S. Colucci Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside J Clin Invest 75 1985 643 649 (Pubitemid 15142075)
42. L.S. Sinoway, C.S. Maskin, B. Chadwick, R. Forman, E.H. Sonnenblick, and T.H. Le Jemtel Long-term therapy with a new cardiotonic agent, win 47203: drug-dependent improvement in cardiac performance and progression of the underlying disease J Am Coll Cardiol 2 1983 327 331 (Pubitemid 13078799)
43. C.S. Maskin, L. Sinoway, B. Chadwick, E.H. Sonnenblick, and T.H. Le Jemtel Sustained hemodynamic and clinical effects of a new cardiotonic agent, win 47203, in patients with severe congestive heart failure Circulation 67 1983 1065 1070 (Pubitemid 13080487)
44. J.L. Anderson Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the united states Am Heart J 121 6 Pt 2 1991 1956 1964
45. E.S. Monrad, R.G. McKay, D.S. Baim, W.S. Colucci, M.A. Fifer, G.V. Heller, H.D. Royal, and W. Grossman Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone Circulation 70 1984 1030 1037 (Pubitemid 15219364)
46. J.B. Shipley, D. Tolman, A. Hastillo, and M.L. Hess Milrinone: basic and clinical pharmacology and acute and chronic management Am J Med Sci 311 1996 286 291
47. R. Grose, J. Strain, M. Greenberg, and T.H. LeJemtel Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure J Am Coll Cardiol 7 1986 1107 1113 (Pubitemid 16103110)
48. J. Gage, H. Rutman, D. Lucido, and T.H. LeJemtel Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure Circulation 74 1986 367 373 (Pubitemid 16072132)
49. E.M. Gilbert, R.E. Hershberger, R.J. Wiechmann, M.A. Movsesian, and M.R. Bristow Pharmacologic and hemodynamic effects of combined beta-agonist stimulation and phosphodiesterase inhibition in the failing human heart Chest 108 1995 1524 1532
50. M.S. Cuffe, R.M. Califf, K.F. Adams Jr. , R. Benza, R. Bourge, W.S. Colucci, B.M. Massie, C.M. O'Connor, I. Pina, and R. Quigg Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial JAMA 287 2002 1541 1547 (Pubitemid 34269999)
51. E. Amsallem, C. Kasparian, G. Haddour, J.P. Boissel, and P. Nony Phosphodiesterase III inhibitors for heart failure Cochrane Database Syst Rev (Online) 1 2005 CD002230
52. C. Yan, C.L. Miller, and J. Abe Regulation of phosphodiesterase 3 and inducible camp early repressor in the heart Circ Res 100 2007 489 501 (Pubitemid 46673258)
53. B. Ding, J. Abe, H. Wei, H. Xu, W. Che, T. Aizawa, W. Liu, C.A. Molina, J. Sadoshima, and B.C. Blaxall A positive feedback loop of phosphodiesterase 3 (pde3) and inducible camp early repressor (icer) leads to cardiomyocyte apoptosis Proc Natl Acad Sci USA 102 2005 14771 14776 (Pubitemid 41457131)
54. G.W. Dorn 2nd. Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling Cardiovasc Res 81 2009 465 473
55. M. Jessup, W.T. Abraham, D.E. Casey, A.M. Feldman, G.S. Francis, T.G. Ganiats, M.A. Konstam, D.M. Mancini, P.S. Rahko, and M.A. Silver 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the american college of cardiology foundation/american heart association task force on practice guidelines: developed in collaboration with the international society for heart and lung transplantation Circulation 119 2009 1977 2016
56. A.L. Marius-Nunez, L. Heaney, R.N. Fernandez, W.A. Clark, A. Ranganini, E. Silber, and P. Denes Intermittent inotropic therapy in an outpatient setting: a cost-effective therapeutic modality in patients with refractory heart failure Am Heart J 132 1996 805 808 (Pubitemid 26366980)
57. D. Cesario, J. Clark, and A. Maisel Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure: a preliminary study Am Heart J 135 1998 121 129 (Pubitemid 28073068)
58. J.N. Nanas, E.P. Tsagalou, J. Kanakakis, S.N. Nanas, J.V. Terrovitis, T. Moon, and M.I. Anastasiou-Nana Long-term intermittent dobutamine infusion, combined with oral amiodarone for end-stage heart failure: a randomized double-blind study Chest 125 2004 1198 1204 (Pubitemid 38501329)
59. S.G. Drakos, J.V. Kanakakis, S. Nanas, M. Bonios, E. Kaldara, F. Katsaros, C. Pantsios, and J.N. Nanas Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure J Cardiovasc Pharmacol 53 2009 157 161
60. A.E. Epstein, J.P. DiMarco, K.A. Ellenbogen, N.A. Estes 3rd, R.A. Freedman, L.S. Gettes, A.M. Gillinov, G. Gregoratos, S.C. Hammill, and D.L. Hayes Acc/aha/hrs 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the american college of cardiology/american heart association task force on practice guidelines (writing committee to revise the acc/aha/naspe 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices): developed in collaboration with the american association for thoracic surgery and society of thoracic surgeons Circulation 117 2008 e350 e408